There are a number of sell-side research firms which cover Inovio Pharmaceuticals, Inc. (NASDAQ:INO) and offer projections on earnings and future stock movement. On a consensus basis, analysts have a one year target price of 22.00 on the equity. The company has a trailing twelve month EPS of -0.30. The consensus analyst estimates according to First Call for the next quarter is -0.12. The current year EPS estimate on the stock is -0.40 and the EPS estimate for next year sits at -0.71.
Company shares opened the most recent trading session at 7.09 and at the time of writing the last Bid was at 7.02. In the current trading session the stock reached as high as 7.11 and dipped down to 7.00. Inovio Pharmaceuticals, Inc., a NMS listed company, has a current market cap of 506.72M and on average over the past 3 months has seen 1265690 shares trade hands on a daily basis.
On a technical level the stock has a 50 Day Moving Average of 6.80. Based on a recent trade, this puts the equity at +3.29% away from that average. In comparing the stock’s current level to its extended history, the stock is trading -35.18% away from its 52-week high of 10.83 and +31.95% away from the stock’s low point over the past 52 weeks, which was 5.32.
The price to earnings ratio, or the valuation ratio of a company’s current share price compared to its per-share earnings sits at N/A. This is an important indicator as a higher ratio typically suggests that investors are expecting higher future earnings growth compared to companies in the same industry with lower price to earnings ratios. When calculating in the EPS estimates for the current year from sell-side analysts, the Price to current year EPS stands at N/A. Investors looking further ahead, will note that the Price to next year’s EPS is N/A.